<code id='A73763BF6A'></code><style id='A73763BF6A'></style>
    • <acronym id='A73763BF6A'></acronym>
      <center id='A73763BF6A'><center id='A73763BF6A'><tfoot id='A73763BF6A'></tfoot></center><abbr id='A73763BF6A'><dir id='A73763BF6A'><tfoot id='A73763BF6A'></tfoot><noframes id='A73763BF6A'>

    • <optgroup id='A73763BF6A'><strike id='A73763BF6A'><sup id='A73763BF6A'></sup></strike><code id='A73763BF6A'></code></optgroup>
        1. <b id='A73763BF6A'><label id='A73763BF6A'><select id='A73763BF6A'><dt id='A73763BF6A'><span id='A73763BF6A'></span></dt></select></label></b><u id='A73763BF6A'></u>
          <i id='A73763BF6A'><strike id='A73763BF6A'><tt id='A73763BF6A'><pre id='A73763BF6A'></pre></tt></strike></i>

          
          WSS

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia